Quick Answer
AEON Biopharma, Inc. reported Stockholders Equity of -$153.04 million for the year ending 2023.
- AEON Biopharma, Inc. showed an increase of +46.8% in Stockholders Equity from 2022 to 2023.
- This data is from AEON Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 29, 2024.
- XBRL data for this metric is available from 2020 to 2023 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $5.00 million | Q1 2021: -$18.84 million | Q2 2021: -$22.84 million | Q3 2021: -$17.18 million | Q4 2021: -$16.93 million | Q1 2022: -$14.16 million | Q2 2022: -$12.37 million | Q3 2022: -$11.55 million | Q1 2023: -$7.32 million | Q2 2023: -$11.46 million | Q3 2023: -$121.74 million | Q4 2023: -$153.04 million | Q1 2024: -$198.38 million | Q2 2024: -$27.95 million | Q3 2024: -$32.09 million | Q4 2024: -$28.57 million | Q1 2025: -$11.32 million | Q2 2025: -$15.85 million | Q3 2025: -$19.87 million.
- Over the full 4 years of available data (2020 to 2023), AEON Biopharma, Inc.'s Stockholders Equity has declined by 714,858.1%.
- Historical annual values: Fiscal year 2023: -$153.04 million | Fiscal year 2022: -$287.50 million | Fiscal year 2021: -$16.93 million | Fiscal year 2020: $21.4 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: